These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2151333)

  • 1. Neutral metalloendopeptidase inhibition: a novel means of circulatory modulation.
    Sybertz EJ; Chiu PJ; Watkins RW; Vemulapalli S
    J Hypertens Suppl; 1990 Dec; 8(7):S161-7. PubMed ID: 2151333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action.
    Sybertz EJ; Chiu PJ; Watkins RW; Vemulapalli S
    Can J Physiol Pharmacol; 1991 Oct; 69(10):1628-35. PubMed ID: 1838029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats.
    Sybertz EJ; Chiu PJ; Vemulapalli S; Pitts B; Foster CJ; Watkins RW; Barnett A; Haslanger MF
    J Pharmacol Exp Ther; 1989 Aug; 250(2):624-31. PubMed ID: 2547941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors.
    Seymour AA; Norman JA; Asaad MM; Fennell SA; Abboa-Offei B; Little DK; Kratunis VJ; Delaney NG; Hunt JT; Di Donato G
    J Pharmacol Exp Ther; 1991 Mar; 256(3):1002-9. PubMed ID: 1826031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator.
    Sybertz EJ
    Clin Nephrol; 1991 Oct; 36(4):187-91. PubMed ID: 1835684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The blood pressure and renal responses to SCH 34826, a neutral metalloendopeptidase inhibitor, and C-ANF (4-23) in Doca-salt hypertensive rats.
    Vemulapalli S; Chiu PJ; Brown A; Griscti K; Sybertz EJ
    Life Sci; 1991; 49(5):383-91. PubMed ID: 1649942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitor.
    Watkins RW; Vemulapalli S; Chiu PJ; Foster C; Smith EM; Neustadt B; Haslanger M; Sybertz EJ
    Am J Hypertens; 1993 May; 6(5 Pt 1):357-68. PubMed ID: 8512660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats.
    Hirata Y; Suzuki E; Hayakawa H; Matsuoka H; Sugimoto T; Kangawa K; Matsuo H
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):283-90. PubMed ID: 7511759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.
    Sybertz EJ; Chiu PJ; Vemulapalli S; Watkins R; Haslanger MF
    Hypertension; 1990 Feb; 15(2):152-61. PubMed ID: 2154404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
    Hirata Y; Suzuki Y; Suzuki E; Hayakawa H; Kimura K; Goto A; Omata M; Minamino N; Kangawa K; Matsuo H
    J Hypertens; 1994 Apr; 12(4):367-74. PubMed ID: 8064160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization and characterization of neutral metalloendopeptidase (EC 3.4.24.11), the degradative enzyme for atrial natriuretic peptide, in rat kidney using a radioiodinated neutral metalloendopeptidase inhibitor.
    Kanazawa M; Casley DJ; Sybertz EJ; Haslanger MF; Johnston CI
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1231-7. PubMed ID: 1534841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
    Nakajima S; Majima M; Ito H; Hayashi I; Yajima Y; Katori M
    Int J Tissue React; 1998; 20(2):45-56. PubMed ID: 9638501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
    J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats.
    Chiu PJ; Tetzloff G; Romano MT; Foster CJ; Sybertz EJ
    Am J Physiol; 1991 Jan; 260(1 Pt 2):R208-16. PubMed ID: 1847022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic inhibition of neutral endopeptidase reduces left ventricular hypertrophy without changing blood pressure in spontaneously hypertensive rats.
    Monopoli A; Forlani A; Ongini E
    J Hypertens Suppl; 1991 Dec; 9(6):S246-7. PubMed ID: 1840189
    [No Abstract]   [Full Text] [Related]  

  • 19. Disparate effects of phosphoramidon on blood pressure in SHR and DOCA-salt hypertensive rats.
    Vemulapalli S; Watkins RW; Brown A; Cook J; Bernardino V; Chiu PJ
    Life Sci; 1993; 53(10):783-93. PubMed ID: 8355566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of 125I-atrial natriuretic factor in anaesthetized rats. Effects of neutral endopeptidase inhibition with candoxatrilat and of ANF-C receptor blockade.
    Barclay PL; Bennett JA; Greengrass PM; Griffin A; Samuels GM; Shepperson NB
    Biochem Pharmacol; 1992 Sep; 44(6):1013-22. PubMed ID: 1417928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.